Antares Pharma Inc

Antares Pharma — Investor Presentation (January 2022)

25 slides from Antares Pharma's investor presentation, Jan 12, 2022

  1. Slide 1: January 2022 Investor Presentation

    1January 2022 NASDAQ: ATRS | January 2022 Investor Presentation EX 99.1

  2. Slide 2: Safe Harbor Statement

    2January 2022 Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are subject to certain risks and uncertainties that can cause actual results

  3. Slide 3: Investment Highlights

    3January 2022 Leverage pharmaceutical and medical device expertise to develop innovative products that address needs in underserved therapeutic areas Investment Highlights Diversified revenue provides opportunities for continued growth Commercial XYOSTED® and NOCDURNA® Commercial Generic EpiPen®, Ge

  4. Slide 4: Long-Term Growth Strategy

    4January 2022 Long-Term Growth Strategy Expand Partnership Opportunities A leader in self-administered injection technology Support life-cycle management solutions Disciplined Capital Allocation Corporate development In-licensing opportunities Enhance Proprietary Portfolio Support research and devel

  5. Slide 5: Rapidly Growing and Diversified Revenue Mix

    5January 2022 42% 34% 10% 14% FY 2020 32% 42% 6% 20% FY 2019 28% 47% 11% 14% FY 2018 Rapidly Growing and Diversified Revenue Mix Proprietary Products Partner Products Development Royalty Revenue $63.6M Revenue $123.9M Revenue $149.6M 43% 23% 12% 22% 9M 2021 Revenue $135.3M

  6. Slide 6: Proprietary Products

    6January 2022 Proprietary Products (desmopressin acetate) sublingual tablet

  7. Slide 7: Patient-Centric Innovation Drives Strategy

    7January 2022 Patient-Centric Innovation Drives Strategy Targeting two therapeutic areas with significant market opportunities UROLOGY & ENDOCRINOLOGY Focus on patient populations with unmet needs Target addressable physician audiences for efficient commercialization Identify and develop innovative,

  8. Slide 8: XYOSTED and In-Licensed TLANDO

    8 Innovative self-delivery of testosterone (T) replacement therapy for at-home use • T levels maintained for as long as the patient remains on therapy* • Convenient, once-a-week dosing • Virtually painless subcutaneous injection ~75% of all commercial lives covered 18 Orange Book listed patents exte

  9. Slide 9: Testosterone Market

    9January 2022 Testosterone Market Once Weekly Painless Efficacious Steady PK No Risk of Transfer 0 500,000 1,000,000 1,500,000 2,000,000 2,500,000 3,000,000 3,500,000 4,000,000 4,500,000 2020 TRT Growth: 6.8% 2020 TRT INJECTABLE Growth: 7.3% 2020 TRT Topical Growth: 1.0% 2020 TRT TRx: 7.6M 2020 TRT

  10. Slide 10: XYOSTED Quarterly TRx Growth

    10January 2022 XYOSTED® Quarterly TRx Growth Written by ~11,000 different physicians (since launch) 3Q 2021 TRx’s increased >40% year-over-year 3Q 2021 TRx’s increased >5% sequentially 3,207 6,485 10,290 14,064 16,777 17,685 21,461 23,274 24,493 27,961 29,795 796 4,517 8,893 13,638 16,387 20,589 22,

  11. Slide 11: Focused Sales Effort to Optimize Current Portfolio

    11January 2022 • Branded TRT and Desmopressin/OAB • ~95% of TRT prescribers in the top 3 deciles is covered • ~50%+ of NOCDURNA® targets are also XYOSTED® targets • Every territory has 120-150 top decile prescriber Recently expanded sales team • 104 FTE: 90 SAR, 12 RSM, 2 ASD • 7 PSR: Flexible ‘virt

  12. Slide 12: In-Licensed: NOCDURNA (desmopressin acetate)

    12January 2022 FDA-approved vasopressin analog indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least two times a night to void • First and only sublingual tablet that targets the kidneys • Short-acting desmopressin is underutilized due to poor disease state

  13. Slide 13: NOCDURNA Works Quickly

    13January 2022 NOCDURNA® Works Quickly A sublingual tablet that dissolves rapidly1 Administered without water1 Onset action occurs within 30 minutes1 Therapeutic effect as early as the first night1 Elimination from the body starts quickly, within a half-life of 2.8 hours1 Antidiuretic effect lasts 6

  14. Slide 14: Antares Assets in Development

    14January 2022 ATRS-1901 Urology Asset Antares Assets in Development ATRS-1902 for Adrenal Crisis Rescue Completed Pre-IND meeting with FDA Filed IND with FDA in June 2021 Reported positive Phase I study results Expect to initiate BE and human factor study in 2022 Expect to file 505(b)(2) NDA with F

  15. Slide 15: ATRS-1902 for Adrenal Crisis Rescue

    15January 2022 ATRS-1902 for Adrenal Crisis Rescue + 62% 6% 6% 12% 14% ENDOCRINOLOGY PEDIATRICS NURSE PRACTITIONER PRIMARY CARE ALL OTHERS Solu-Cortef® Prescribers(4) Simple (2-step), integrated device versus standard-of-care, Solu-Cortef® sterile powder that requires reconstitution and multiple ste

  16. Slide 16: Partner Business: Deep Device Knowledge

    16January 2022 Deep Device Knowledge Partner Business: Extensive Regulatory Expertise and Success Tailored Durable Asset Development PHARMACEUTICAL TECHNOLOGY PARTNER $0.0 $20.0 $40.0 $60.0 $80.0 $100.0 2015 2016 2017 2018 2019 2020 9M 2021 Partner Product License and Development Royalties $32.4 $46

  17. Slide 17: Commercial Experience: Teva's Generic EpiPen

    17January 2022 Commercial Experience Teva’s Generic EpiPen FDA-approved as therapeutically equivalent to Mylan’s EpiPen® and fully substitutable at the pharmacy Antares receives cost plus margin on all devices sold to Teva plus mid-to-high, single-digit royalties on net sales EpiPen, Jr. launched in

  18. Slide 18: Generic EpiPen Quarterly TRx Prescription Trends

    18January 2022 Generic EpiPen® Quarterly TRx Prescription Trends Bloomberg/Symphony Health Solutions 28,750 / 6% 125,000 / 22% 237,000 / 27% 183,000 / 36% 206,000 / 43% 176,000 / 38% 293,000 / 43% 232,000 / 48% 305,000 / 53% 445,000 / 58% 561,000 / 58% 448,750 568,000 862,000 506,000 484,000 465,000

  19. Slide 19: Generic Forteo (teriparatide)

    19January 2022 Teva launched ROW 12 European countries Israel and Canada Forteo® 2020 revenue $510 million in U.S. by Lilly $536 million in ROW by Lilly Attractive economics to ATRS Supply devices at reasonable margin Royalties escalating to mid-teens Potential FDA approval Expect fully substitutabl

  20. Slide 20: Global Development Agreement with Idorsia for Selatogrel

    20January 2022 Global Development Agreement with Idorsia Pharmaceuticals for selatogrel, a New Chemical Entity, with the QuickShot® auto injector selatogrel Selatogrel is a potent and highly selective P2Y12 receptor antagonist intended for the treatment of suspected Acute Myocardial Infarction (AMI)

  21. Slide 21: Myocardial Infarction Market Opportunity

    21January 2022 • ~800,000 occurrences of new or recurrent MI1 annually • 600,000 have a first MI + 200,000 have a recurrent MI Myocardial Infarction Market Opportunity 1. Mozaffarian D et al. Circulation 2016 * American Heart Association ~8.4 million Americans* have survived a Myocardial Infarction

  22. Slide 22: Diversified Product Portfolio

    22January 2022 Diversified Product Portfolio Testosterone Desmopressin Acetate Sumatriptan Epinephrine Hydroxyprogesterone Teriparatide Testosterone Teriparatide Exenatide P2Y12 Receptor Antagonist Undisclosed Hydrocortisone Undisclosed Undisclosed XYOSTED® NOCDURNA® SUMATRIPTAN EPINEPHRINE MAKENA®

  23. Slide 23: Revenue Growth and 2021 Projections

    23January 2022 45% 50% 51% 59% 58% 64% 0% 10% 20% 30% 40% 50% 60% 70% 2016 2017 2018 2019 2020 9M 2021 Gross Margin $52.2M $54.5M $63.6M $123.9M $149.6M $180-190M* 2016 2017 2018 2019 2020 2021 +4% vs. 2016 +21% vs. 2019 +17% vs. 2017 +95% vs. 2018 Revenue Growth and 2021 Projections Projected 5-Yea

  24. Slide 24: 2022 Invest and Grow Strategy

    24January 2022 2022 Invest and Grow Strategy Internal Pipeline Expansion Commercial Expansion of Organizational Structure and Capabilities Corporate Development New scalable structure to support future growth Efficient and scalable Leveraging resources to accelerate opportunities New candidates and

  25. Slide 25: Antares Pharma: Long-Term Value Proposition

    25January 2022 Antares Pharma: Long-Term Value Proposition Diverse portfolio of commercialized products Multiple growth drivers • Continued XYOSTED® prescription growth • Continued generic EpiPen® prescription growth • Relaunch of NOCDURNA® • Pending FDA approval and commercial launch of TLANDO® • P

Antares Pharma — Investor Presentation (January 2022) on 6ix